{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T17:02:22Z","timestamp":1789578142510,"version":"build-2803163510"},"reference-count":176,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T00:00:00Z","timestamp":1741219200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Molecular bases of disease dissemination in lymphoid malignancies to optimize curative therapeutic strategies","award":["21198"],"award-info":[{"award-number":["21198"]}]},{"name":"Molecular bases of disease dissemination in lymphoid malignancies to optimize curative therapeutic strategies","award":["PNRR-MAD-2022-12375673"],"award-info":[{"award-number":["PNRR-MAD-2022-12375673"]}]},{"name":"Molecular bases of disease dissemination in lymphoid malignancies to optimize curative therapeutic strategies","award":["M6\/C2_CALL 2022"],"award-info":[{"award-number":["M6\/C2_CALL 2022"]}]},{"DOI":"10.13039\/501100003196","name":"Universit\u00e0 del Piemonte Orientale, Novara, Italy","doi-asserted-by":"publisher","award":["21198"],"award-info":[{"award-number":["21198"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Universit\u00e0 del Piemonte Orientale, Novara, Italy","doi-asserted-by":"publisher","award":["PNRR-MAD-2022-12375673"],"award-info":[{"award-number":["PNRR-MAD-2022-12375673"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Universit\u00e0 del Piemonte Orientale, Novara, Italy","doi-asserted-by":"publisher","award":["M6\/C2_CALL 2022"],"award-info":[{"award-number":["M6\/C2_CALL 2022"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Next Generation EU","award":["21198"],"award-info":[{"award-number":["21198"]}]},{"name":"Next Generation EU","award":["PNRR-MAD-2022-12375673"],"award-info":[{"award-number":["PNRR-MAD-2022-12375673"]}]},{"name":"Next Generation EU","award":["M6\/C2_CALL 2022"],"award-info":[{"award-number":["M6\/C2_CALL 2022"]}]},{"name":"Italian MoH, Rome, Italy","award":["21198"],"award-info":[{"award-number":["21198"]}]},{"name":"Italian MoH, Rome, Italy","award":["PNRR-MAD-2022-12375673"],"award-info":[{"award-number":["PNRR-MAD-2022-12375673"]}]},{"name":"Italian MoH, Rome, Italy","award":["M6\/C2_CALL 2022"],"award-info":[{"award-number":["M6\/C2_CALL 2022"]}]},{"name":"AIL Novara VCO ODV, Novara, Italy","award":["21198"],"award-info":[{"award-number":["21198"]}]},{"name":"AIL Novara VCO ODV, Novara, Italy","award":["PNRR-MAD-2022-12375673"],"award-info":[{"award-number":["PNRR-MAD-2022-12375673"]}]},{"name":"AIL Novara VCO ODV, Novara, Italy","award":["M6\/C2_CALL 2022"],"award-info":[{"award-number":["M6\/C2_CALL 2022"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Histological transformation (HT) into aggressive lymphoma is a turning point in a significant fraction of patients affected by indolent lymphoproliferative neoplasms, namely, chronic lymphocytic leukemia (CLL), follicular lymphoma (FL), marginal zone lymphomas (MZLs), and lymphoplasmacytic lymphoma (LPL) [...]<\/jats:p>","DOI":"10.3390\/cancers17050907","type":"journal-article","created":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T09:59:17Z","timestamp":1741255157000},"page":"907","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Molecular Mechanisms in the Transformation from Indolent to Aggressive B Cell Malignancies"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-9307-1965","authenticated-orcid":false,"given":"Nawar","family":"Maher","sequence":"first","affiliation":[{"name":"Division of Hematology, Department of Translational Medicine, Universit\u00e0 del Piemonte Orientale and Azienda Ospedaliero-Universitaria Maggiore della Carit\u00e0, 28100 Novara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samir","family":"Mouhssine","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Translational Medicine, Universit\u00e0 del Piemonte Orientale and Azienda Ospedaliero-Universitaria Maggiore della Carit\u00e0, 28100 Novara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-6981-7426","authenticated-orcid":false,"given":"Bassam Francis","family":"Matti","sequence":"additional","affiliation":[{"name":"Department of Hematology and Bone Marrow Transplant, Hematology and Bone Marrow Transplant Center, Medical City, Baghdad 00964, Iraq"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4757-8064","authenticated-orcid":false,"given":"Alaa Fadhil","family":"Alwan","sequence":"additional","affiliation":[{"name":"Department of Clinical Hematology, The National Center of Hematology, Mustansiriyah University, Baghdad 10001, Iraq"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4681-0151","authenticated-orcid":false,"given":"Gianluca","family":"Gaidano","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Translational Medicine, Universit\u00e0 del Piemonte Orientale and Azienda Ospedaliero-Universitaria Maggiore della Carit\u00e0, 28100 Novara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,3,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Mouhssine, S., and Gaidano, G. (2022). Richter Syndrome: From Molecular Pathogenesis to Druggable Targets. Cancers, 14.","DOI":"10.3390\/cancers14194644"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.hoc.2020.02.001","article-title":"Epidemiology of Follicular Lymphoma","volume":"34","author":"Cerhan","year":"2020","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1093\/annonc\/mdv368","article-title":"Histologic transformation in marginal zone lymphomas","volume":"26","author":"Conconi","year":"2015","journal-title":"Ann. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1002\/ajh.24477","article-title":"Histological transformation to diffuse large B-cell lymphoma in patients with Waldenstr\u00f6m macroglobulinemia","volume":"91","author":"Castillo","year":"2016","journal-title":"Am. J. Hematol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1053\/j.seminhematol.2023.11.002","article-title":"DLBCL arising from indolent lymphomas: How are they different?","volume":"60","author":"Parry","year":"2023","journal-title":"Semin. Hematol."},{"key":"ref_6","first-page":"381","article-title":"Malignant Lymphoma: A Clinico-Pathologic Survey of 618 Cases","volume":"18","author":"Gall","year":"1942","journal-title":"Am. J. Pathol."},{"key":"ref_7","unstructured":"Swerdlow, S.H., Campo, E., Harris, N.L., Jaffe, E.S., Pileri, S.A., Stein, H., and Thiele, J. (2017). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, International Agency for Research on Cancer Lyon. [4th ed.]."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"key":"ref_9","unstructured":"Surveillance Epidemiology and End Results Program (SEER) (2024, December 21). Cancer Stat Facts: Leukemia\u2014Chronic Lymphocytic Leukemia (CLL), Available online: https:\/\/seer.cancer.gov\/statfacts\/html\/clyl.html."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Mouhssine, S., Maher, N., Matti, B.F., Alwan, A.F., and Gaidano, G. (2024). Targeting BTK in B Cell Malignancies: From Mode of Action to Resistance Mechanisms. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25063234"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Maher, N., Mouhssine, S., Matti, B.F., Alwan, A.F., and Gaidano, G. (2023). Treatment Refractoriness in Chronic Lymphocytic Leukemia: Old and New Molecular Biomarkers. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241210374"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1001\/jama.2023.1946","article-title":"Diagnosis and Treatment of Chronic Lymphocytic Leukemia: A Review","volume":"329","author":"Shadman","year":"2023","journal-title":"JAMA"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"270","DOI":"10.3390\/hematolrep16020027","article-title":"Current Therapeutic Sequencing in Chronic Lymphocytic Leukemia","volume":"16","author":"Mouhssine","year":"2024","journal-title":"Hematol. Rep."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.annonc.2024.06.016","article-title":"ESMO Clinical Practice Guideline interim update on new targeted therapies in the first line and at relapse of chronic lymphocytic leukaemia","volume":"35","author":"Eichhorst","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1182\/blood-2018-01-791376","article-title":"Biology and treatment of Richter syndrome","volume":"131","author":"Rossi","year":"2018","journal-title":"Blood"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/s41375-024-02492-4","article-title":"Incidence of Richter transformation of chronic lymphocytic leukemia\/small lymphocytic lymphoma in the targeted therapy era","volume":"39","author":"Hampel","year":"2024","journal-title":"Leukemia"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1038\/s41591-022-01927-8","article-title":"Detection of early seeding of Richter transformation in chronic lymphocytic leukemia","volume":"28","author":"Nadeu","year":"2022","journal-title":"Nat. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/s41375-020-0797-x","article-title":"Richter transformation in chronic lymphocytic leukemia (CLL)\u2014A pooled analysis of German CLL Study Group (GCLLSG) front line treatment trials","volume":"35","author":"Robrecht","year":"2021","journal-title":"Leukemia"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1097\/PAS.0b013e31804bdaf8","article-title":"IgVH mutational status and clonality analysis of Richter\u2019s transformation: Diffuse large B-cell lymphoma and Hodgkin lymphoma in association with B-cell chronic lymphocytic leukemia (B-CLL) represent 2 different pathways of disease evolution","volume":"31","author":"Mao","year":"2007","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_20","first-page":"514","article-title":"Immunophenotypic and genomic landscape of Richter transformation diffuse large B-cell lymphoma","volume":"55","author":"Medeiros","year":"2023","journal-title":"Pathology"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","article-title":"Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray","volume":"103","author":"Hans","year":"2004","journal-title":"Blood"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"765","DOI":"10.3324\/haematol.2019.224121","article-title":"Clinical characteristics and outcomes of Richter transformation: Experience of 204 patients from a single center","volume":"105","author":"Wang","year":"2020","journal-title":"Haematologica"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1111\/bjh.18352","article-title":"Clonally unrelated Richter syndrome are truly de novo diffuse large B-cell lymphomas with a mutational profile reminiscent of clonally related Richter syndrome","volume":"198","author":"Favini","year":"2022","journal-title":"Br. J. Haematol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1200\/JCO.22.01028","article-title":"Emerging Therapies for the Management of Richter Transformation","volume":"41","author":"Smyth","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1056\/NEJM198711053171904","article-title":"Molecular analysis of the t(14;18) chromosomal translocation in malignant lymphomas","volume":"317","author":"Weiss","year":"1987","journal-title":"N. Engl. J. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1002\/ajh.26737","article-title":"Follicular lymphoma: 2023 update on diagnosis and management","volume":"97","author":"Jacobsen","year":"2022","journal-title":"Am. J. Hematol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41572-019-0132-x","article-title":"Follicular lymphoma","volume":"5","author":"Carbone","year":"2019","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s00277-017-3151-2","article-title":"Transformed follicular lymphoma","volume":"97","author":"Fischer","year":"2018","journal-title":"Ann. Hematol."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Alcoceba, M., Garc\u00eda-\u00c1lvarez, M., Medina, A., Maldonado, R., Gonz\u00e1lez-Calle, V., Chill\u00f3n, M.C., Sarasquete, M.E., Gonz\u00e1lez, M., Garc\u00eda-Sanz, R., and Jim\u00e9nez, C. (2022). MYD88 Mutations: Transforming the Landscape of IgM Monoclonal Gammopathies. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23105570"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/ng.2856","article-title":"Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma","volume":"46","author":"Okosun","year":"2014","journal-title":"Nat. Genet."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.celrep.2013.12.027","article-title":"Genetics of follicular lymphoma transformation","volume":"6","author":"Pasqualucci","year":"2014","journal-title":"Cell Rep."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1200\/JCO.2012.48.3990","article-title":"Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: A report from the University of Iowa\/MayoClinic Specialized Program of Research Excellence Molecular Epidemiology Resource","volume":"31","author":"Link","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1002\/hon.3152","article-title":"Marginal zone lymphomas","volume":"41","author":"Zucca","year":"2023","journal-title":"Hematol. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.21037\/aol-20-28","article-title":"Epidemiology of Marginal Zone Lymphoma","volume":"5","author":"Cerhan","year":"2021","journal-title":"Ann. Lymphoma"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1002\/ajh.27058","article-title":"Marginal zone lymphoma: 2023 update on diagnosis and management","volume":"98","author":"Cheah","year":"2023","journal-title":"Am. J. Hematol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3324\/haematol.2021.278755","article-title":"Marginal zone lymphoma: Present status and future perspectives","volume":"107","author":"Cheah","year":"2022","journal-title":"Haematologica"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1002\/ajh.25600","article-title":"Clinical and molecular characteristics of lymphoplasmacytic lymphoma not associated with an IgM monoclonal protein: A multicentric study of the Rete Ematologica Lombarda (REL) network","volume":"94","author":"Varettoni","year":"2019","journal-title":"Am. J. Hematol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/s41408-023-00896-6","article-title":"The oncogenic human B-cell lymphoma MYD88 L265P mutation genocopies activation by phosphorylation at the Toll\/interleukin-1 receptor (TIR) domain","volume":"13","author":"Minderman","year":"2023","journal-title":"Blood Cancer J."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1053\/j.seminhematol.2023.03.008","article-title":"The epidemiology of Waldenstr\u00f6m macroglobulinemia","volume":"60","author":"McMaster","year":"2023","journal-title":"Semin. Hematol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/s41375-020-01102-3","article-title":"CXCR4 in Waldenstr\u00f6m\u2019s Macroglobulinema: Chances and challenges","volume":"35","author":"Kaiser","year":"2021","journal-title":"Leukemia"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e976","DOI":"10.1097\/HS9.0000000000000976","article-title":"Clonal Relationship and Mutation Analysis in Lymphoplasmacytic Lymphoma\/Waldenstr\u00f6m Macroglobulinemia Associated With Diffuse Large B-cell Lymphoma","volume":"7","author":"Berendsen","year":"2023","journal-title":"HemaSphere"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Condoluci, A., and Rossi, D. (2022). Biology and Treatment of Richter Transformation. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.829983"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1007\/s12032-013-0800-8","article-title":"Hodgkin lymphoma transformation of chronic lymphocytic leukemia: Cases report and discussion","volume":"31","author":"Balcerzak","year":"2014","journal-title":"Med. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1002\/cncr.20773","article-title":"Richter syndrome: Biology, incidence, and therapeutic strategies","volume":"103","author":"Tsimberidou","year":"2005","journal-title":"Cancer"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Mahmoud, A.M., Gaidano, G., and Mouhssine, S. (2023). Immunological Aspects of Richter Syndrome: From Immune Dysfunction to Immunotherapy. Cancers, 15.","DOI":"10.3390\/cancers15041015"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1182\/blood-2010-09-302174","article-title":"The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation","volume":"117","author":"Rossi","year":"2011","journal-title":"Blood"},{"key":"ref_47","first-page":"e104","article-title":"S101\u2014The Landscape of TP53 Mutations and Their Prognostic Impact in Chronic Lymphocytic Leukemia\u2014EHA2024 Hybrid Congress","volume":"8","author":"Bertossi","year":"2024","journal-title":"HemaSphere"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.ejca.2017.06.023","article-title":"Mutant p53 as a target for cancer treatment","volume":"83","author":"Duffy","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Zhang, H., Xu, J., Long, Y., Maimaitijiang, A., Su, Z., Li, W., and Li, J. (2024). Unraveling the Guardian: p53\u2019s Multifaceted Role in the DNA Damage Response and Tumor Treatment Strategies. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms252312928"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1038\/s41418-022-00988-z","article-title":"Cell cycle regulation: p53-p21-RB signaling","volume":"29","author":"Engeland","year":"2022","journal-title":"Cell Death Differ."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1038\/sj.cdd.4401903","article-title":"p53 in recombination and repair","volume":"13","author":"Gatz","year":"2006","journal-title":"Cell Death Differ."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1126\/science.1092734","article-title":"Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis","volume":"303","author":"Chipuk","year":"2004","journal-title":"Science"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1038\/s41419-021-03902-6","article-title":"Puma, noxa, p53, and p63 differentially mediate stress pathway induced apoptosis","volume":"12","author":"Wang","year":"2021","journal-title":"Cell Death Dis."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1084\/jem.20131448","article-title":"Genetic lesions associated with chronic lymphocytic leukemia transformation to Richter syndrome","volume":"210","author":"Fabbri","year":"2013","journal-title":"J. Exp. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1002\/wdev.40","article-title":"Ink4-Arf locus in cancer and aging","volume":"1","author":"Sherr","year":"2012","journal-title":"Wiley Interdiscip. Rev. Dev. Biol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/35096061","article-title":"The INK4a\/ARF network in tumour suppression","volume":"2","author":"Sherr","year":"2001","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nrc2399","article-title":"Cellular mechanisms of tumour suppression by the retinoblastoma gene","volume":"8","author":"Burkhart","year":"2008","journal-title":"Nat. Rev. Cancer"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41392-024-02080-z","article-title":"Cyclin-dependent protein kinases and cell cycle regulation in biology and disease","volume":"10","author":"Pellarin","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Hern\u00e1ndez Borrero, L.J., and El-Deiry, W.S. (2021). Tumor suppressor p53: Biology, signaling pathways, and therapeutic targeting. Biochim. Biophys. Acta Rev. Cancer, 1876.","DOI":"10.1016\/j.bbcan.2021.188556"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1182\/blood.2020008276","article-title":"B-cell receptor signaling and genetic lesions in TP53 and CDKN2A\/CDKN2B cooperate in Richter transformation","volume":"138","author":"Chakraborty","year":"2021","journal-title":"Blood"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1084\/jem.20110921","article-title":"Analysis of the chronic lymphocytic leukemia coding genome: Role of NOTCH1 mutational activation","volume":"208","author":"Fabbri","year":"2011","journal-title":"J. Exp. Med."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"3593","DOI":"10.1242\/dev.063610","article-title":"Notch signaling: Simplicity in design, versatility in function","volume":"138","author":"Andersson","year":"2011","journal-title":"Development"},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Rosati, E., Baldoni, S., De Falco, F., Del Papa, B., Dorillo, E., Rompietti, C., Albi, E., Falzetti, F., Di Ianni, M., and Sportoletti, P. (2018). NOTCH1 Aberrations in Chronic Lymphocytic Leukemia. Front. Oncol., 8.","DOI":"10.3389\/fonc.2018.00229"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/s41392-022-00934-y","article-title":"Notch signaling pathway: Architecture, disease, and therapeutics","volume":"7","author":"Zhou","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1111\/j.1365-2141.2009.07816.x","article-title":"A new genetic lesion in B-CLL: A NOTCH1 PEST domain mutation","volume":"146","author":"Baldoni","year":"2009","journal-title":"Br. J. Haematol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1038\/leu.2016.383","article-title":"Mutations in NOTCH1 PEST domain orchestrate CCL19-driven homing of chronic lymphocytic leukemia cells by modulating the tumor suppressor gene DUSP22","volume":"31","author":"Arruga","year":"2017","journal-title":"Leukemia"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1111\/j.1365-2141.2012.09155.x","article-title":"Different impact of NOTCH1 and SF3B1 mutations on the risk of chronic lymphocytic leukemia transformation to Richter syndrome","volume":"158","author":"Rossi","year":"2012","journal-title":"Br. J. Haematol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41571-021-00549-2","article-title":"The MYC oncogene\u2014The grand orchestrator of cancer growth and immune evasion","volume":"19","author":"Dhanasekaran","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"18261","DOI":"10.1073\/pnas.0606108103","article-title":"NOTCH1 directly regulates c-MYC and activates a feed-forward-loop transcriptional network promoting leukemic cell growth","volume":"103","author":"Palomero","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.3109\/10428194.2012.723706","article-title":"MGA, a suppressor of MYC, is recurrently inactivated in high risk chronic lymphocytic leukemia","volume":"54","author":"Cerri","year":"2013","journal-title":"Leuk. Lymphoma"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1182\/blood.2022016272","article-title":"Macrophage- and BCR- but not TLR-derived signals support the growth of CLL and Richter Syndrome murine models in vivo","volume":"140","author":"Martines","year":"2022","journal-title":"Blood"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1182\/blood-2010-05-284984","article-title":"The lymph node microenvironment promotes B-cell receptor signaling, NF-\u03baB activation, and tumor proliferation in chronic lymphocytic leukemia","volume":"117","author":"Herishanu","year":"2011","journal-title":"Blood"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.1182\/blood-2002-02-0539","article-title":"Constitutively activated phosphatidylinositol-3 kinase (PI-3K) is involved in the defect of apoptosis in B-CLL: Association with protein kinase Cdelta","volume":"100","author":"Ringshausen","year":"2002","journal-title":"Blood"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1182\/blood.2020005734","article-title":"Active Akt signaling triggers CLL toward Richter transformation via overactivation of Notch1","volume":"137","author":"Kohlhaas","year":"2021","journal-title":"Blood"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/nature11309","article-title":"Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling","volume":"489","author":"Schneider","year":"2012","journal-title":"Nature"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.it.2013.07.002","article-title":"B cell receptor signaling in chronic lymphocytic leukemia","volume":"34","author":"Burger","year":"2013","journal-title":"Trends Immunol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1182\/blood.2020010029","article-title":"Exploring the pathways to chronic lymphocytic leukemia","volume":"138","author":"Stevenson","year":"2021","journal-title":"Blood"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1182\/blood-2006-03-012948","article-title":"Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: Pathogenetic implications and clinical correlations","volume":"109","author":"Stamatopoulos","year":"2007","journal-title":"Blood"},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Gerousi, M., Laidou, S., Gemenetzi, K., Stamatopoulos, K., and Chatzidimitriou, A. (2021). Distinctive Signaling Profiles With Distinct Biological and Clinical Implications in Aggressive CLL Subsets With Stereotyped B-Cell Receptor Immunoglobulin. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.771454"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"4415","DOI":"10.1158\/1078-0432.CCR-08-3266","article-title":"Stereotyped B-cell receptor is an independent risk factor of chronic lymphocytic leukemia transformation to Richter syndrome","volume":"15","author":"Rossi","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"4902","DOI":"10.1182\/blood-2013-02-486209","article-title":"Association between molecular lesions and specific B-cell receptor subsets in chronic lymphocytic leukemia","volume":"121","author":"Rossi","year":"2013","journal-title":"Blood"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"3580","DOI":"10.1182\/blood-2014-09-603217","article-title":"Excessive antigen reactivity may underlie the clinical aggressiveness of chronic lymphocytic leukemia stereotyped subset #8","volume":"125","author":"Gounari","year":"2015","journal-title":"Blood"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/s41375-024-02499-x","article-title":"Immunoglobulin light chain mutational status refines IGHV prognostic value in identifying chronic lymphocytic leukemia patients with early treatment requirement","volume":"39","author":"Nabki","year":"2024","journal-title":"Leukemia"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"16824","DOI":"10.1002\/jcp.28358","article-title":"PD-1\/PD-L1 pathway: Basic biology and role in cancer immunotherapy","volume":"234","author":"Salmaninejad","year":"2019","journal-title":"J. Cell Physiol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/s41408-021-00477-5","article-title":"Distinct immune signatures in chronic lymphocytic leukemia and Richter syndrome","volume":"11","author":"Wang","year":"2021","journal-title":"Blood Cancer J."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/bjh.15514","article-title":"PD-1 is highly expressed by neoplastic B-cells in Richter transformation","volume":"185","author":"Behdad","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Li, X., Du, H., Zhan, S., Liu, W., Wang, Z., Lan, J., PuYang, L., Wan, Y., Qu, Q., and Wang, S. (2022). The interaction between the soluble programmed death ligand-1 (sPD-L1) and PD-1(+) regulator B cells mediates immunosuppression in triple-negative breast cancer. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.830606"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1158\/2159-8290.CD-15-1408","article-title":"PD-1hi Identifies a Novel Regulatory B-cell Population in Human Hepatoma That Promotes Disease Progression","volume":"6","author":"Xiao","year":"2016","journal-title":"Cancer Discov."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.molimm.2019.02.009","article-title":"PD-1-expressing B cells suppress CD4+ and CD8+ T cells via PD-1\/PD-L1-dependent pathway","volume":"109","author":"Wang","year":"2019","journal-title":"Mol. Immunol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"594841","DOI":"10.3389\/fimmu.2020.594841","article-title":"Microenvironment Remodeling and Subsequent Clinical Implications in Diffuse Large B-Cell Histologic Variant of Richter Syndrome","volume":"11","author":"Notarantonio","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1084\/jem.171.5.1393","article-title":"LAG-3, a novel lymphocyte activation gene closely related to CD4","volume":"171","author":"Triebel","year":"1990","journal-title":"Journal of Experimental Medicine"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1093\/intimm\/11.11.1745","article-title":"The MHC class II ligand lymphocyte activation gene-3 is co-distributed with CD8 and CD3\u2013TCR molecules after their engagement by mAb or peptide\u2013MHC class I complexes","volume":"11","author":"Hannier","year":"1999","journal-title":"Int. Immunol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"101305","DOI":"10.1016\/j.smim.2019.101305","article-title":"Lymphocyte-activation gene 3 (LAG3): The next immune checkpoint receptor","volume":"42","author":"Ruffo","year":"2019","journal-title":"Semin. Immunol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"5173","DOI":"10.4049\/jimmunol.1002050","article-title":"MHC Class II Engagement by Its Ligand LAG-3 (CD223) Contributes to Melanoma Resistance to Apoptosis","volume":"186","author":"Hemon","year":"2011","journal-title":"J. Immunol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/cei.13407","article-title":"TIGIT as an emerging immune checkpoint","volume":"200","author":"Guillerey","year":"2020","journal-title":"Clin. Exp. Immunol."},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Huang, Z., Qi, G., Miller, J.S., and Zheng, S.G. (2020). CD226: An Emerging Role in Immunologic Diseases. Front. Cell Dev. Biol., 8.","DOI":"10.3389\/fcell.2020.00564"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"3718","DOI":"10.1182\/blood-2021-150183","article-title":"The Tigit\/CD226\/CD155 Immunomodulatory Axis Is Deregulated in CLL and Contributes to B-Cell Anergy","volume":"138","author":"Arruga","year":"2021","journal-title":"Blood"},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Arruga, F., Gyau, B.B., Iannello, A., Vitale, N., Vaisitti, T., and Deaglio, S. (2020). Immune Response Dysfunction in Chronic Lymphocytic Leukemia: Dissecting Molecular Mechanisms and Microenvironmental Conditions. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21051825"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1016\/S1470-2045(24)00396-6","article-title":"Atezolizumab, venetoclax, and obinutuzumab combination in Richter transformation diffuse large B-cell lymphoma (MOLTO): A multicentre, single-arm, phase 2 trial","volume":"25","author":"Tedeschi","year":"2024","journal-title":"Lancet Oncol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1038\/s41591-023-02722-9","article-title":"Tislelizumab plus zanubrutinib for Richter transformation: The phase 2 RT1 trial","volume":"30","author":"Ligtvoet","year":"2024","journal-title":"Nat. Med."},{"key":"ref_101","first-page":"11","article-title":"Richter syndrome: Novel insights into the biology of transformation","volume":"142","author":"Parry","year":"2023","journal-title":"Blood"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/s41591-022-02113-6","article-title":"Evolutionary history of transformation from chronic lymphocytic leukemia to Richter syndrome","volume":"29","author":"Parry","year":"2023","journal-title":"Nat. Med."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1002\/hon.2221","article-title":"XIII. Molecular pathogenesis of transformed lymphomas","volume":"33","author":"Rossi","year":"2015","journal-title":"Hematol. Oncol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"615","DOI":"10.3390\/hemato3040042","article-title":"Genetics of Transformed Follicular Lymphoma","volume":"3","author":"Alcoceba","year":"2022","journal-title":"Hemato"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1158\/1078-0432.CCR-13-2175","article-title":"Inactivation of the CDKN2A tumor-suppressor gene by deletion or methylation is common at diagnosis in follicular lymphoma and associated with poor clinical outcome","volume":"20","author":"Alhejaily","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"4677","DOI":"10.1182\/blood.V91.12.4677","article-title":"Homozygous deletions at chromosome 9p21 involving p16 and p15 are associated with histologic progression in follicle center lymphoma","volume":"91","author":"Gascoyne","year":"1998","journal-title":"Blood"},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Kridel, R., Chan, F.C., Mottok, A., Boyle, M., Farinha, P., Tan, K., Meissner, B., Bashashati, A., McPherson, A., and Roth, A. (2016). Histological Transformation and Progression in Follicular Lymphoma: A Clonal Evolution Study. PLoS Med., 13.","DOI":"10.1371\/journal.pmed.1002197"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1182\/blood-2018-06-855502","article-title":"miR-150 downregulation contributes to the high-grade transformation of follicular lymphoma by upregulating FOXP1 levels","volume":"132","author":"Musilova","year":"2018","journal-title":"Blood"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1182\/blood-2008-05-154013","article-title":"The presence of TP53 mutation at diagnosis of follicular lymphoma identifies a high-risk group of patients with shortened time to disease progression and poorer overall survival","volume":"112","author":"Taylor","year":"2008","journal-title":"Blood"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1182\/blood.V82.8.2289.2289","article-title":"p53 mutations are associated with histologic transformation of follicular lymphoma","volume":"82","author":"Gaidano","year":"1993","journal-title":"Blood"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1038\/sj.leu.2403802","article-title":"A limited role for TP53 mutation in the transformation of follicular lymphoma to diffuse large B-cell lymphoma","volume":"19","author":"Davies","year":"2005","journal-title":"Leukemia"},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"Yang, H., and Green, M.R. (2019). Epigenetic Programing of B-Cell Lymphoma by BCL6 and Its Genetic Deregulation. Front. Cell Dev. Biol., 7.","DOI":"10.3389\/fcell.2019.00272"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/nature03147","article-title":"The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells","volume":"432","author":"Phan","year":"2004","journal-title":"Nature"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1038\/ni1478","article-title":"Bcl-6 mediates the germinal center B cell phenotype and lymphomagenesis through transcriptional repression of the DNA-damage sensor ATR","volume":"8","author":"Ranuncolo","year":"2007","journal-title":"Nat. Immunol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1038\/ni1245","article-title":"BCL6 interacts with the transcription factor Miz-1 to suppress the cyclin-dependent kinase inhibitor p21 and cell cycle arrest in germinal center B cells","volume":"6","author":"Phan","year":"2005","journal-title":"Nat. Immunol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1126\/science.8235596","article-title":"Alterations of a zinc finger-encoding gene, BCL-6, in diffuse large-cell lymphoma","volume":"262","author":"Ye","year":"1993","journal-title":"Science"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"361","DOI":"10.3343\/alm.2020.40.5.361","article-title":"Diagnostic Approach for Double-Hit and Triple-Hit Lymphoma Based on Immunophenotypic and Cytogenetic Characteristics of Bone Marrow Specimens","volume":"40","author":"Kim","year":"2020","journal-title":"Ann. Lab. Med."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1182\/blood-2015-06-649905","article-title":"Cell of origin of transformed follicular lymphoma","volume":"126","author":"Kridel","year":"2015","journal-title":"Blood"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1182\/blood-2002-08-2482","article-title":"BCL6 gene translocation in follicular lymphoma: A harbinger of eventual transformation to diffuse aggressive lymphoma","volume":"102","author":"Akasaka","year":"2003","journal-title":"Blood"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1038\/sj.leu.2404856","article-title":"Distinctive patterns of BCL6 molecular alterations and their functional consequences in different subgroups of diffuse large B-cell lymphoma","volume":"21","author":"Iqbal","year":"2007","journal-title":"Leukemia"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1182\/blood-2013-05-500595","article-title":"Genome-wide copy-number analyses reveal genomic abnormalities involved in transformation of follicular lymphoma","volume":"123","author":"Bouska","year":"2014","journal-title":"Blood"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"17023","DOI":"10.1038\/sigtrans.2017.23","article-title":"NF-\u03baB signaling in inflammation","volume":"2","author":"Liu","year":"2017","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"12203","DOI":"10.1074\/jbc.273.20.12203","article-title":"MyD88, an adapter protein involved in interleukin-1 signaling","volume":"273","author":"Burns","year":"1998","journal-title":"J. Biol. Chem."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"41443","DOI":"10.1074\/jbc.M301742200","article-title":"Structural complementarity of Toll\/interleukin-1 receptor domains in Toll-like receptors and the adaptors Mal and MyD88","volume":"278","author":"Dunne","year":"2003","journal-title":"J. Biol. Chem."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"41661","DOI":"10.1074\/jbc.M102262200","article-title":"IRAK-mediated translocation of TRAF6 and TAB2 in the interleukin-1-induced activation of NFkappa B","volume":"276","author":"Qian","year":"2001","journal-title":"J. Biol. Chem."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"97","DOI":"10.12703\/P6-97","article-title":"MyD88: A central player in innate immune signaling","volume":"6","author":"Deguine","year":"2014","journal-title":"F1000Prime Rep."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/leu.2016.175","article-title":"Combined copy number and mutation analysis identifies oncogenic pathways associated with transformation of follicular lymphoma","volume":"31","author":"Bouska","year":"2017","journal-title":"Leukemia"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1002\/gcc.22184","article-title":"Amplification of 2p as a genomic marker for transformation in lymphoma","volume":"53","author":"Kwiecinska","year":"2014","journal-title":"Genes Chromosomes Cancer"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/j.1365-2141.2006.06439.x","article-title":"Transformation of follicular lymphoma to diffuse large B-cell lymphoma proceeds by distinct oncogenic mechanisms","volume":"136","author":"Davies","year":"2007","journal-title":"Br. J. Haematol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/j.1600-065X.2009.00783.x","article-title":"The CD160, BTLA, LIGHT\/HVEM pathway: A bidirectional switch regulating T-cell activation","volume":"229","author":"Cai","year":"2009","journal-title":"Immunol. Rev."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nri1917","article-title":"Balancing co-stimulation and inhibition with BTLA and HVEM","volume":"6","author":"Murphy","year":"2006","journal-title":"Nat. Rev. Immunol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1182\/blood-2008-08-174953","article-title":"Regions of acquired uniparental disomy at diagnosis of follicular lymphoma are associated with both overall survival and risk of transformation","volume":"113","author":"Gupta","year":"2009","journal-title":"Blood"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41408-020-00395-y","article-title":"Genetic complexity impacts the clinical outcome of follicular lymphoma patients","volume":"11","author":"Sarasquete","year":"2021","journal-title":"Blood Cancer J."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1182\/blood-2008-02-140616","article-title":"Genome-wide profiling of follicular lymphoma by array comparative genomic hybridization reveals prognostically significant DNA copy number imbalances","volume":"113","author":"Cheung","year":"2009","journal-title":"Blood"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1182\/blood-2015-10-679191","article-title":"TNFRSF14 aberrations in follicular lymphoma increase clinically significant allogeneic T-cell responses","volume":"128","author":"Kotsiou","year":"2016","journal-title":"Blood"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.cell.2016.08.032","article-title":"Loss of the HVEM Tumor Suppressor in Lymphoma and Restoration by Modified CAR-T Cells","volume":"167","author":"Boice","year":"2016","journal-title":"Cell"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3960\/jslrt.19003","article-title":"High TNFRSF14 and low BTLA are associated with poor prognosis in Follicular Lymphoma and in Diffuse Large B-cell Lymphoma transformation","volume":"59","author":"Carreras","year":"2019","journal-title":"J. Clin. Exp. Hematop."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.beha.2016.08.029","article-title":"Transformation of marginal zone lymphoma (and association with other lymphomas)","volume":"30","author":"Casulo","year":"2017","journal-title":"Best. Pr. Res. Clin. Haematol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"4174","DOI":"10.1158\/1078-0432.CCR-14-2759","article-title":"Genetics and Prognostication in Splenic Marginal Zone Lymphoma: Revelations from Deep Sequencing","volume":"21","author":"Parry","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1084\/jem.20120904","article-title":"The coding genome of splenic marginal zone lymphoma: Activation of NOTCH2 and other pathways regulating marginal zone development","volume":"209","author":"Rossi","year":"2012","journal-title":"J. Exp. Med."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1084\/jem.20120910","article-title":"Whole-genome sequencing identifies recurrent somatic NOTCH2 mutations in splenic marginal zone lymphoma","volume":"209","author":"Kiel","year":"2012","journal-title":"J. Exp. Med."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/nrm2009","article-title":"Notch signalling: A simple pathway becomes complex","volume":"7","author":"Bray","year":"2006","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"9265","DOI":"10.1128\/MCB.24.21.9265-9273.2004","article-title":"Notch subunit heterodimerization and prevention of ligand-independent proteolytic activation depend, respectively, on a novel domain and the LNR repeats","volume":"24","author":"Carpenter","year":"2004","journal-title":"Mol. Cell Biol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.3324\/haematol.11635","article-title":"NOTCH2 mutations in marginal zone lymphoma","volume":"93","author":"Wlodarska","year":"2008","journal-title":"Haematologica"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"3695","DOI":"10.1182\/bloodadvances.2022009415","article-title":"Unraveling the genetics of transformed splenic marginal zone lymphoma","volume":"7","author":"Grau","year":"2023","journal-title":"Blood Adv."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1182\/blood-2010-02-267476","article-title":"Cytogenetic aberrations and their prognostic value in a series of 330 splenic marginal zone B-cell lymphomas: A multicenter study of the Splenic B-Cell Lymphoma Group","volume":"116","author":"Salido","year":"2010","journal-title":"Blood"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1182\/blood-2010-01-264275","article-title":"Genome-wide DNA profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcome","volume":"117","author":"Rinaldi","year":"2011","journal-title":"Blood"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1038\/leu.2013.365","article-title":"Whole-exome sequencing in splenic marginal zone lymphoma reveals mutations in genes involved in marginal zone differentiation","volume":"28","author":"Almaraz","year":"2014","journal-title":"Leukemia"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1111\/j.1365-2141.2012.09226.x","article-title":"High-throughput sequencing analysis of the chromosome 7q32 deletion reveals IRF5 as a potential tumour suppressor in splenic marginal-zone lymphoma","volume":"158","author":"Fresquet","year":"2012","journal-title":"Br. J. Haematol."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1007\/s12026-013-8463-2","article-title":"A20-mediated negative regulation of canonical NF-\u03baB signaling pathway","volume":"57","author":"Pujari","year":"2013","journal-title":"Immunol. Res."},{"key":"ref_151","doi-asserted-by":"crossref","unstructured":"Jaramillo Oquendo, C., Parker, H., Oscier, D., Ennis, S., Gibson, J., and Strefford, J.C. (2019). Systematic Review of Somatic Mutations in Splenic Marginal Zone Lymphoma. Sci. Rep., 9.","DOI":"10.1038\/s41598-019-46906-1"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1182\/blood.2021012386","article-title":"Genetic and phenotypic attributes of splenic marginal zone lymphoma","volume":"139","author":"Bonfiglio","year":"2022","journal-title":"Blood"},{"key":"ref_153","doi-asserted-by":"crossref","unstructured":"Wittner, J., and Schuh, W. (2023). Kr\u00fcppel-like factor 2: A central regulator of B cell differentiation and plasma cell homing. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1172641"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1182\/blood-2016-02-696757","article-title":"The genetics of nodal marginal zone lymphoma","volume":"128","author":"Spina","year":"2016","journal-title":"Blood"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1038\/leu.2014.330","article-title":"KLF2 mutation is the most frequent somatic change in splenic marginal zone lymphoma and identifies a subset with distinct genotype","volume":"29","author":"Clipson","year":"2015","journal-title":"Leukemia"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.gene.2017.06.056","article-title":"Histone H3 lysine 4 methyltransferase KMT2D","volume":"627","author":"Froimchuk","year":"2017","journal-title":"Gene"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1182\/blood-2014-08-596247","article-title":"DNA methylation profiling identifies two splenic marginal zone lymphoma subgroups with different clinical and genetic features","volume":"125","author":"Arribas","year":"2015","journal-title":"Blood"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.beha.2016.09.003","article-title":"Methylation patterns in marginal zone lymphoma","volume":"30","author":"Arribas","year":"2017","journal-title":"Best. Pr. Res. Clin. Haematol."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1200\/JCO.2006.05.6150","article-title":"Forkhead box protein P1 expression in mucosa-associated lymphoid tissue lymphomas predicts poor prognosis and transformation to diffuse large B-cell lymphoma","volume":"24","author":"Sagaert","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1038\/sj.leu.2403644","article-title":"T(3;14)(p14.1;q32) involving IGH and FOXP1 is a novel recurrent chromosomal aberration in MALT lymphoma","volume":"19","author":"Streubel","year":"2005","journal-title":"Leukemia"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1038\/sj.leu.2404244","article-title":"Genetic rearrangement of FOXP1 is predominantly detected in a subset of diffuse large B-cell lymphomas with extranodal presentation","volume":"20","author":"Haralambieva","year":"2006","journal-title":"Leukemia"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.1182\/blood-2004-03-1209","article-title":"Strong expression of FOXP1 identifies a distinct subset of diffuse large B-cell lymphoma (DLBCL) patients with poor outcome","volume":"104","author":"Barrans","year":"2004","journal-title":"Blood"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1002\/ajh.25694","article-title":"Deletion 20q12 is associated with histological transformation of nodal marginal zone lymphoma to diffuse large B-cell lymphoma","volume":"95","author":"Qian","year":"2020","journal-title":"Am. J. Hematol."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1111\/bjh.15049","article-title":"MYD88 wild-type Waldenstrom Macroglobulinaemia: Differential diagnosis, risk of histological transformation, and overall survival","volume":"180","author":"Treon","year":"2018","journal-title":"Br. J. Haematol."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1182\/blood-2013-09-525808","article-title":"The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis","volume":"123","author":"Hunter","year":"2014","journal-title":"Blood"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.3324\/haematol.2017.172718","article-title":"Pattern of somatic mutations in patients with Waldenstr\u00f6m macroglobulinemia or IgM monoclonal gammopathy of undetermined significance","volume":"102","author":"Varettoni","year":"2017","journal-title":"Haematologica"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1146\/annurev.immunol.18.1.217","article-title":"The biology of chemokines and their receptors","volume":"18","author":"Rossi","year":"2000","journal-title":"Annu. Rev. Immunol."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/leu.2014.187","article-title":"The WHIM-like CXCR4(S338X) somatic mutation activates AKT and ERK, and promotes resistance to ibrutinib and other agents used in the treatment of Waldenstrom\u2019s Macroglobulinemia","volume":"29","author":"Cao","year":"2015","journal-title":"Leukemia"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/s41392-023-01347-1","article-title":"Targeting p53 pathways: Mechanisms, structures and advances in therapy","volume":"8","author":"Wang","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_170","doi-asserted-by":"crossref","unstructured":"Weber, L.I., and Hartl, M. (2023). Strategies to target the cancer driver MYC in tumor cells. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1142111"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/s41392-020-00312-6","article-title":"Targeting NF-\u03baB pathway for the therapy of diseases: Mechanism and clinical study","volume":"5","author":"Yu","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"7016","DOI":"10.1182\/blood-2022-163753","article-title":"FISH Analysis of CDKN2A\/B Deletion in Chronic Lymphocytic Leukemia","volume":"140","author":"Teierle","year":"2022","journal-title":"Blood"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.1182\/blood.2020005650","article-title":"Genomic and transcriptomic correlates of Richter transformation in chronic lymphocytic leukemia","volume":"137","author":"Klintman","year":"2021","journal-title":"Blood"},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1038\/leu.2016.134","article-title":"Genomic disruption of the histone methyltransferase SETD2 in chronic lymphocytic leukaemia","volume":"30","author":"Parker","year":"2016","journal-title":"Leukemia"},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"2970","DOI":"10.21037\/tcr-23-1396","article-title":"A STEP ahead for CAR-T cell therapy of large B cell lymphoma: Understanding the molecular determinants of resistance","volume":"12","author":"Mouhssine","year":"2023","journal-title":"Transl. Cancer Res."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ccell.2022.12.005","article-title":"Determinants of resistance to engineered T cell therapies targeting CD19 in large B cell lymphomas","volume":"41","author":"Sworder","year":"2023","journal-title":"Cancer Cell"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/5\/907\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:48:26Z","timestamp":1760028506000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/5\/907"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,6]]},"references-count":176,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["cancers17050907"],"URL":"https:\/\/doi.org\/10.3390\/cancers17050907","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,6]]}}}